Omnicell Inc (OMCL) valuation
Omnicell P/E ratio history
Omnicell trades at 43.6 times its earnings over the last twelve months and 17.1 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 57.2 (year to Dec 2019) to 420.2 (year to Dec 2022), with a median of 120.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $45.30 | $0.04 | n/m | 25.1 |
| Dec 31, 2024 | $44.52 | $0.27 | 164.9 | 25.0 |
| Dec 31, 2023 | $37.63 | -$0.45 | n/m | 21.7 |
| Dec 31, 2022 | $50.42 | $0.12 | 420.2 | — |
| Dec 31, 2021 | $180.44 | $1.62 | 111.4 | 44.2 |
| Dec 31, 2020 | $120.02 | $0.74 | 162.2 | — |
| Dec 31, 2019 | $81.72 | $1.43 | 57.2 | — |
| Dec 31, 2018 | $61.24 | $0.93 | 65.9 | — |
| Dec 31, 2017 | $48.50 | $0.79 | 61.4 | — |
| Dec 31, 2016 | $33.90 | $0.26 | 130.4 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Omnicell valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| OmnicellOMCL | $1.67B | 43.6 | 17.1 | 1.3 |
| Nuvation BioNUVB | $1.66B | — | — | 9.8 |
| Replimune GroupREPL | $1.66B | — | — | — |
| NovavaxNVAX | $1.66B | — | — | 4.0 |
| PersonalisPSNL | $1.66B | — | — | 23.8 |
| Ani PharmaceuticalsANIP | $1.64B | 15.7 | 7.4 | 1.7 |
| Stoke TherapeuticsSTOK | $1.64B | — | — | 59.3 |
| Butterfly NetworkBFLY | $1.70B | — | — | 13.8 |
| Sonida Senior LivingSNDA | $1.62B | — | — | 3.1 |
| Peer median | 15.7 | 7.4 | 9.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: OMCL financials · OMCL returns
No forecast, no recommendation. This page describes Omnicell Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.